Barentz acquires Anshul Life Sciences to strengthen India portfolio
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
GSK and Flagship to jointly fund up to $150 million upfront
Report highlights significant improvements in adolescent well-being in India
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Subscribe To Our Newsletter & Stay Updated